I am pleased to share that this quarter has been a positive one for Vimta Labs, with total income of X1,005 mn, reflecting a YoY growth of 10.2%. This performance underscores our continued focus on excellence in scientific research, operational discipline, and customer trust. Strong demand across our service offerings, coupled with improved operational efficiencies, has resulted in healthy growth and resilient EBITDA margins of 34.3% (after considering Exceptional item — New Labour Codes impact). Our teams have demonstrated exceptional commitment to quality, enabling us to further strengthen Vimta’s position as a preferred partner for both regulated and emerging markets. Looking ahead, we remain confident in our strategic direction and will continue to invest in capabilities that enhance long-term value for our clients, stakeholders, and the broader people wellness ecosystem.”